United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Expect to see data this month from several clinical trials that are trying to establish if “mixing and matching” different COVID-19 vaccines is safe and effective or if it's better to get the same booster as the one used in the primary series of shots.

Allowing people to mix COVID-19 vaccines could cut into Pfizer and Moderna's revenue next year

Merck

Could Pfizer's COVID Pill Be Better Than Merck's?

AbbVie

AstraZeneca

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Sanofi

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

On Tuesday, Pfizer Inc. (NYSE:PFE) shares edged slightly higher after The Lancet published a report showing its covid-19 vaccine weakens after six months. According to the findings from a large population study, Pfizer's and BioNTech's covid-19 vaccine's effectiveness reduced from 88% to 47% after five months.

Is Pfizer stock a buy after study reveals the need for booster shots?

The efficacy of Pfizer and BioNTech's Covid-19 vaccine against infection dropped over the course of five months, but protection against hospitalizations remained consistent, according to a real-world study.

Pfizer's Covid Vaccine Loses Effectiveness Against Infection Over Time. What To Know.

Atea Pharmaceuticals

Merck, Pfizer, and Atea are set to do battle next year in the COVID-19 pill market.

Which COVID-19 Pill Stock Is the Best Buy?

The effectiveness of the Pfizer-BioNTech vaccine against infection by COVID-19 falls to 47% six months after the second vaccine dose, a new study shows. The peer-review analysis, which was published in the Lancet medical journal, found that two doses of the vaccine were 90% effective against COVID-19 hospitalisation for at least six months, but only 47% effective against infection after that period.

COVID-19: Pfizer vaccine protection drops to 47% after six months

Pfizer and OPKO Health's human growth hormone drug, somatrogon, could be approved by the U.S. Food and Drug Administration next January.

This Growth Hormone Drug Could Be a Boost For Pfizer

Canadian Imperial Bank of Commerce

PepsiCo

They'll pay you much more than the paltry return you'll get with the average stock in the S&P 500.

3 Safe Dividend Stocks to Buy Right Now

BioNTech SE

Two doses of the Pfizer-BioNTech vaccine are 90% effective against COVID-19 hospitalisation for at least six months but only 47% effective against infection after that period, according to a new study.

Pfizer-BioNTech vaccine effectiveness wanes to 47% against COVID-19 infection after six months

Pfizer Inc (NYSE: PFE) and its partner BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine's effectiveness against the disease wanes with time but its protection against hospitalization remains, as per a study. What Happened: The vaccine's effectiveness declined from a peak of 88% a month after receiving the two-shots to 47% six months later, as per the study published by The Lancet.

Pfizer COVID-19 Vaccine Effectiveness Wanes But The Shot Is Good For Keeping People Out Of Hospitals, Says Study

In the latest trading session, Pfizer (PFE) closed at $42.42, marking a -1.19% move from the previous day.

Pfizer (PFE) Stock Moves -1.19%: What You Should Know

Protection against the virus itself wanes to about 50% during that period, but vaccination still wards off severe disease.

Pfizer Covid Vaccine Still 90% Effective At Preventing Hospitalizations After Six Months, Study Finds

Researchers found the effectiveness of Pfizer's vaccine against the delta variant was 93% a month after the second dose and fell to 53% after four months.

Pfizer Covid shot protects people from hospitalization even as effectiveness against infection falls, Lancet study confirms

The European Medicine Agency's Committee for Medicinal Products for Human Use has recommended COVID-19 booster shots from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for adults 18 years and older. Related:   Johnson & Johnson To Seek FDA Approval For COVID-19 Booster Shot: Report.

Pfizer/BioNTech COVID-19 Booster Shots Get Recommendation From European Medicine Agency

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Pfizer (PFE) a Great Value Stock Right Now?

Are we seeing a major shift into oral medications for COVID? Our Foolish roundtable picks three of the strongest stocks in this rising subsector.

3 Stocks That Might Soar With Pills for COVID

QuidelOrtho Corp

These could be good hedges to help offset the pandemic-related risks.

2 Growth Stocks to Buy if You're Worried COVID Is Here to Stay

A federal court has rejected Pfizer's PFE, -0.31% claims against the government in a case with major implications for drug pricing.

Pfizer loses legal battle with big implications for drug pricing

Novavax

Vaxart

Good news from Merck and Ridgeback caused these stocks to fall.

Why Pfizer, BioNTech, Novavax, and Vaxart Stocks Are Sinking Today

A judge dismissed Pfizer Inc's challenge to a U.S. anti-kickback law that the drugmaker said prevents it from helping Medicare patients afford two drugs that treat a sometimes fatal heart condition, but which cost $225,000 a year.

Pfizer loses lawsuit over U.S. limits on drug copay assistance

Barings BDC Inc

FirstEnergy

Redwood Trust

After the September slump, more volatility may be awaiting October, which calls for investing in risk-adjusted stocks like BARINGS BDC (BBDC), FirstEnergy (FE), Pfizer (PFE) & Redwood Trust (RWT).

4 of the Best Stocks to Counter a Volatile October

Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.

Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal

Kadmon Hlds

Novo Nordisk

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Pfizer Inc's (NYSE: PFE) Cibinqo (abrocitinib) for atopic dermatitis (AD). Related content:  Benzinga's Full  FDA Calendar.

News for Pfizer Stock (PFE)